iCardiac announced that it has been selected to work on an early phase oncology clinical trial with a global Japanese pharma company.
iCardiac announced that it has been selected to work on an early phase oncology clinical trial with a global Japanese pharma company. This study will utilize iCardiac’s Rapid QT service offering, which assists trial sites in making accurate patient inclusion/exclusion decisions.
Read the full release here
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.